Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 03, 2005. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 925,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,474.00 pence per share.
- Treasury Shares Held: 123,158,000 shares (post-transaction).
- Shares in Issue: 5,825,219,052 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback executed on November 03, 2005, authorized by shareholders at the Annual General Meeting on May 25, 2005. The filing text does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 925,000 share repurchase based on the disclosed price of 1,474.00 pence.
- Confirm the updated total share capital structure (5,825,219,052 issued shares plus 123,158,000 treasury shares).
- Review the Annual General Meeting minutes from May 25, 2005, to understand the full scope of the share buyback authorization.